



**HAL**  
open science

## Geographic distribution of anti-*Leptospira* antibodies in humans in Côte d'Ivoire, West Africa

Stephane Kouadio Koffi, Syndou Meite, Abdoulaye Ouattara, Stephane Kan Kouassi, Sylla Aboubacar, Veronique Agbaya Akran, Pascale Bourhy, Mireille Dosso

### ► To cite this version:

Stephane Kouadio Koffi, Syndou Meite, Abdoulaye Ouattara, Stephane Kan Kouassi, Sylla Aboubacar, et al.. Geographic distribution of anti-*Leptospira* antibodies in humans in Côte d'Ivoire, West Africa. *European Journal of Clinical Microbiology and Infectious Diseases*, 2018, 37 (11), pp.2177-2180. 10.1007/s10096-018-3359-7 . pasteur-03251358

**HAL Id: pasteur-03251358**

**<https://pasteur.hal.science/pasteur-03251358>**

Submitted on 7 Jun 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 Geographic distribution of anti-*Leptospira* antibodies in humans in Côte  
2 d'Ivoire, West Africa.

3

4 Koffi Kouadio Stephane<sup>1,2</sup>, Meite Syndou<sup>1</sup>, Ouattara Abdoulaye<sup>1</sup>, Kouassi Kan Stephane<sup>1</sup>, Sylla  
5 Aboubacar<sup>1</sup>, Akran Agbaya Veronique<sup>1</sup>, Bourhy Pascale<sup>3</sup>, Dosso Mireille<sup>1</sup>.

6 1 : Institut Pasteur de Côte d'Ivoire

7 2 : UFR Sciences médicales Université F. Houphouët-Boigny/CHU de Cocody

8 3 : Centre National de Référence de la leptospirose, Institut Pasteur de Paris

9

10 Corresponding author

11 KOFFI Kouadio Stéphane

12 08 BP 919 Abidjan 08

13 Tel: (225) 05788663

14 Koffi.ks@gmail.com

15 **INTRODUCTION**

16 Leptospirosis is a zoonotic bacterial disease with a worldwide distribution caused by pathogenic  
17 bacteria of the genus *Leptospira* [1]. It is an endemic disease especially in subtropical and tropical  
18 regions and outbreaks can occur after heavy rain or flooding [1]. Transmission occurs through direct or  
19 indirect contact with urine of infected animals [1, 2].

20 Leptospirosis may be unrecognized or misdiagnosed because of the lack of specific clinical symptoms,  
21 thus human incidence is commonly underreported.

22 The World Health Organization (WHO) Leptospirosis Epidemiology Reference Group (LERG)  
23 estimated the leptospirosis incidence at 1.03 million cases and 58,900 deaths each year worldwide [3].  
24 West African annual leptospirosis incidence was estimated to be 9.7 per 100,000 population [3].

25 In West Africa, few studies on *Leptospira* prevalence have been published. And prevalence of acute  
26 human leptospirosis ranged from 0.0% to 7.8% in five studies on symptomatic patients [4, 5].

27 In Côte d'Ivoire, data are sparse, however an unpublished study carried out in 2013 by the "Centre  
28 Suisse de Recherche Scientifique" in Yopougon (Abidjan) showed, 4% prevalence in both 124 febrile  
29 patients and 99 rodents using MAT showing human and animal infection. Another study showed high  
30 prevalence in 93 vaccinated dogs (58%) and 63 non-vaccinated dogs (47%) sampled in Abidjan and in  
31 two neighbouring cities using MAT suggesting human exposure [6].

32 Thus, little is known about leptospirosis in the country and data are needed to inform burden estimates  
33 and to inform intervention strategies. Mapping leptospirosis exposure could help find high-risk areas  
34 and lead intervention choices against the disease. This study aims to determine the geographic  
35 distribution of anti-*Leptospira* antibodies in humans in Côte d'Ivoire.

36

37 **MATERIAL AND METHODS**

38 This study was carried out from August to November 2015 in the 82 health districts of Côte d'Ivoire.

39 The study was carry out on stored human specimens previously collected for the national surveillance  
40 system for communicable diseases in 2014. Only negative specimens were included in the study.

41 One to 13 serum samples were randomly selected per health district based on the number of notified  
42 cases by health districts in the year to obtain a sample size of 384.

43 Blood samples were collected from each patient who matches the clinical WHO's case definition for  
44 notifiable disease. Samples were sent, at +4°C, to the National Reference Centre at the Institut Pasteur  
45 de Côte d'Ivoire for analysis. Anti-*Leptospira* antibody testing was carried out at Institut Pasteur de  
46 Côte d'Ivoire (IPCI) and Institut Pasteur in Paris (IP). We used as screening methods the ELISA  
47 against type IgG anti-*Leptospira* antibodies previously describe by Bourhy et al. (2013) in IPCI [7].  
48 Confirmation was carried out by MAT in IP with a threshold of 1:50. As antigens, 16 serogroups were  
49 used (table 1).

50 Socio-demographic and clinical data from the National Reference Centre, which manage the samples  
51 and results for analysis performed on studied samples, were used to build a database using Epi Info  
52 software (CDC, Atlanta, Georgia). Data analyses were done using R software 3.2.0 [8].

53

54 **RESULTS**

55 Age of patients ranged from 1 month to 78 years old with a mean age of 20.8 years. Patients less than  
56 25 years were more represented with 60.9% of all patients. We noted a male predominance with a sex  
57 ratio of 1.55.

58 Of the samples tested, ELISA positively screened 90. Of these, 36 were confirmed by MAT  
59 representing 9.4 % prevalence. People with anti-*Leptospira* antibodies had a mean age of 34.5 years  
60 and a Sex ratio of 2. Of the 82 health districts of the country, anti-*Leptospira* antibodies were found in  
61 samples from 22. Health districts with anti-*Leptospira* antibodies were mostly located in the western  
62 and the southern parts of the country (fig 1).

63 MAT anti-*Leptospira* antibodies titre ranged from 1:50 to 1:6400. Eight different serogroups of  
64 *Leptospira* were found (table 2). Serogroup Panama was the most frequent (36.1 %) followed by  
65 Louisiana (19.4 %) and Grippotyphosa and Sejroe (11.1% respectively).

66

67 **DISCUSSION**

68 This study focuses on anti-*Leptospira* antibodies in human specimens collected in the national  
69 surveillance system for communicable diseases in Côte d'Ivoire. Few published data on *Leptospira* and  
70 leptospirosis in Côte d'Ivoire are available [4, 5, 9]. Our study, which focus on type IgG antibodies  
71 showed a prevalence of 9.4%. This result is in accordance with the LERG who estimated an annual  
72 incidence for leptospirosis to 9.6 % in the West sub-Saharan Africa WHO region [3].

73 Samples from all the 82 health districts of the country were included in this study. So, the studied  
74 population were representative of all the country. However, health districts with anti-*Leptospira*  
75 antibodies found in this study were mostly located in the western and the southern parts of the country  
76 (fig 1). These parts of the country are peculiar by their climate and forest cover. They are the most  
77 humid parts of the country with higher forest cover and heavy raining season compare to the northern  
78 part of the country, which is mostly arid. It's actually well known that leptospirosis is related to water  
79 and wet soils were *Leptospira* find proper conditions for his maintenance in the environment [10, 11,  
80 12]. In these parts of the country, some irrigated farming activities like rice, banana and vegetable  
81 farming are associated with risk behaviours like walking barefooted in wet farm soil, sludge or working  
82 without wearing appropriated personal protective equipment. The maintenance of *Leptospira* in the  
83 environment is better when bacteria are protected from direct UV sunlight [13]. This situation could be  
84 achieved in forests or in large farms with trees like cocoa, coffee or rubber plantations mostly seen in  
85 the western and southern part of the country. These plantations also offer habitats to small mammals  
86 that are considered a reservoir of bacteria and create a Human/ Animal/ Environment interface, which  
87 could improve the transmission of the disease.

88 Regarding people with anti-*Leptospira* antibodies, they were young adults (mean age 34.5 years)  
89 mostly men (sex ratio 2) living in rural area; corresponding to active low-income farmers working into  
90 agricultural fields. These people could represent an at-risk population and it could be suitable to  
91 implement prevention activities against leptospirosis related to them. Indeed, farming is a major  
92 activity in Côte d'Ivoire representing 43.5 % of jobs.

93 This study highlights the circulation of leptospirosis among people in Côte d'Ivoire. Unfortunately, no  
94 routine laboratory-based diagnostic strategies are available for leptospirosis or other diseases such as  
95 rickettsia or viral hepatitis. Numerous patients suffering from infectious diseases are not correctly  
96 diagnosed, and the burden of these diseases is underestimated. Early diagnosis and treatment reduce  
97 occurrence of complications and improve recovery rate significantly [1]. There is a need to improve  
98 public health by Ivorian authorities and their international partners.

99

100 **COMPLIANCE WITH ETHICAL STANDARDS**

101 **Funding:** No funding was received.

102 **Conflict of Interest:** The authors declare that they have no conflict of interest.

103 **Ethical approval:** The national ethic and research committee of Côte d'Ivoire approved this study  
104 under the number 23/MSLS/CNER-dkn.

105 **Informed consent:** Not applicable.

106

107 **REFERENCES**

- 108 1. Haake DA, Levett PN (2015) Leptospirosis in humans. *Curr Top Microbiol Immunol* 387:65-97.  
109 doi: 10.1007/978-3-662-45059-8\_5.
- 110 2. Hartskeerl RA, Collares-Pereira M, Ellis WA (2011) Emergence, control and re-emerging  
111 leptospirosis: dynamics of infection in the changing world. *Clinical Microbiology and Infection*  
112 17:494–501. doi: 10.1111/j.1469-0691.2011.03474.x.
- 113 3. Costa F, Hagan JE, Calcagno J, Kane M, Torgerson P, Martinez-Silveira MS, Stein C, Abela-  
114 Ridder B, Ko AI. (2015) Global Morbidity and Mortality of Leptospirosis: A Systematic Review.  
115 *PLoS Negl Trop Dis* 9: e0003898. doi: 10.1371/journal.pntd.0003898.
- 116 4. De Vries SG, Visser BJ, Nagel IM, Goris MG, Hartskeerl RA, Grobusch MP (2014) Leptospirosis  
117 in Sub-Saharan Africa: a systematic review. *Int J Infect Dis* 28:47-64.

- 118 5. Allan KJ, Biggs HM, Halliday JEB, Kazwala RR, Maro VP, Cleaveland S, Crump JA. (2015)  
119 Epidemiology of Leptospirosis in Africa: A Systematic Review of a Neglected Zoonosis and a  
120 Paradigm for 'One Health' in Africa. Plos Neglected Tropical Diseases 9: 3899–3899.  
121 6. Roqueplo C, Marié JL, André-Fontaine G, Kodjo A, Davoust B (2015) Serological survey of  
122 canine leptospirosis in three countries of tropical Africa: Sudan, Gabon and Ivory Coast. Comp  
123 Immunol Microbiol Infect Dis 38:57-61. doi: 10.1016/j.cimid.2014.10.006.  
124 7. Bourhy P, Vray M, Picardeau M (2013) Evaluation of an in-house ELISA using the intermediate  
125 species *Leptospira fainei* for diagnosis of leptospirosis. J Med Microbiol 62(Pt 6):822-7.  
126 8. R Core Team (2015) R: A language and environment for statistical computing. R Foundation for  
127 Statistical Computing, Vienna, Austria. URL <http://www.R-project.org>  
128 9. Pappas G, Papadimitriou P, Siozopoulou V, Christou L, Akritidis N (2008) The globalization of  
129 leptospirosis: worldwide incidence trends. Int J Infect Dis 12(4):351-7. Epub 2007 Dec 4.  
130 10. Adler B, De La Pena Moctezuma A (2010) *Leptospira* and leptospirosis. Veterinary Microbiology  
131 140: 287–296. doi: 10.1016/j.vetmic.2009.03.012.  
132 11. Faine S, Adler B, Bolin C, Pérolat P (1999) *Leptospira* and leptospirosis. Melbourne, Australia:  
133 MediSci. 296 p.  
134 12. Levett PN (2001) Leptospirosis. Clinical Microbiology Reviews 14(2):296–326.  
135 13. Stamm LV, Charon NW (1988) Sensitivity of pathogenic and free-living *Leptospira spp.* to UV  
136 radiation and mitomycin C. Appl Environ Microbiol 54(3): 728–733.

137

#### 138 **FIGURE CAPTIONS**

139 **Fig 1** shows health districts where people with anti-*Leptospira* antibodies were found. Colors are related  
140 to number of cases found